141 related articles for article (PubMed ID: 26494857)
1. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
Cesca M; Morosi L; Berndt A; Fuso Nerini I; Frapolli R; Richter P; Decio A; Dirsch O; Micotti E; Giordano S; D'Incalci M; Davoli E; Zucchetti M; Giavazzi R
Mol Cancer Ther; 2016 Jan; 15(1):125-35. PubMed ID: 26494857
[TBL] [Abstract][Full Text] [Related]
2. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
[TBL] [Abstract][Full Text] [Related]
3. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
4. Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors.
Torok S; Rezeli M; Kelemen O; Vegvari A; Watanabe K; Sugihara Y; Tisza A; Marton T; Kovacs I; Tovari J; Laszlo V; Helbich TH; Hegedus B; Klikovits T; Hoda MA; Klepetko W; Paku S; Marko-Varga G; Dome B
Theranostics; 2017; 7(2):400-412. PubMed ID: 28042343
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.
Awasthi N; Zhang C; Schwarz AM; Hinz S; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575
[TBL] [Abstract][Full Text] [Related]
6. MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.
Nishidate M; Yamamoto K; Masuda C; Aikawa H; Hayashi M; Kawanishi T; Hamada A
Sci Rep; 2017 Dec; 7(1):16763. PubMed ID: 29196706
[TBL] [Abstract][Full Text] [Related]
7. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
[TBL] [Abstract][Full Text] [Related]
8. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
9. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
Chen YF; Yuan A; Cho KH; Lu YC; Kuo MY; Chen JH; Chang YC
PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
[TBL] [Abstract][Full Text] [Related]
10. DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma.
Hauge A; Gaustad JV; Huang R; Simonsen TG; Wegner CS; Andersen LMK; Rofstad EK
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):666-676. PubMed ID: 30858145
[TBL] [Abstract][Full Text] [Related]
11. Investigation of combination therapy modes of bevacizumab and paclitaxel for NSCLC in vivo.
Wang J; Shen H; Jiang Q; Shu Y
Pak J Pharm Sci; 2016 Mar; 29(2 Suppl):695-9. PubMed ID: 27113309
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
[TBL] [Abstract][Full Text] [Related]
13. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
14. VEGF165b Mutant Promotes the Apoptosis of Murine Breast Cancer Cells Induced by Paclitaxel by Inducing Tumor Vessel Maturation.
Liang C; Li Y; Guo E; Bai S; Wang Y; Zhang H
Protein Pept Lett; 2023; 30(11):951-958. PubMed ID: 37861033
[TBL] [Abstract][Full Text] [Related]
15. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
16. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab improves the delivery and efficacy of paclitaxel.
Yanagisawa M; Yorozu K; Kurasawa M; Nakano K; Furugaki K; Yamashita Y; Mori K; Fujimoto-Ouchi K
Anticancer Drugs; 2010 Aug; 21(7):687-94. PubMed ID: 20559127
[TBL] [Abstract][Full Text] [Related]
18. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
19. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
20. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Cesca M; Frapolli R; Berndt A; Scarlato V; Richter P; Kosmehl H; D'Incalci M; Ryan AJ; Giavazzi R
Neoplasia; 2009 Nov; 11(11):1155-64. PubMed ID: 19881951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]